Phio Pharmaceuticals Corp. (PHIO)
0.808
+0.01
(+1.00%)
USD |
NASDAQ |
Nov 06, 10:23
Phio Pharmaceuticals Enterprise Value : -3.702M for Nov. 5, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 05, 2026 | -3.702M |
| November 04, 2026 | -2.890M |
| November 03, 2026 | -2.506M |
| November 02, 2026 | -2.773M |
| October 30, 2026 | -3.005M |
| October 29, 2026 | -2.975M |
| October 28, 2026 | -2.345M |
| October 27, 2026 | -2.643M |
| October 26, 2026 | -3.119M |
| October 23, 2026 | -3.094M |
| October 22, 2026 | -2.86M |
| October 21, 2026 | -2.600M |
| October 20, 2026 | -2.632M |
| October 19, 2026 | -2.902M |
| October 16, 2026 | -2.876M |
| October 15, 2026 | -2.241M |
| October 14, 2026 | -1.964M |
| October 13, 2026 | -2.140M |
| October 12, 2026 | -2.285M |
| October 09, 2026 | -1.625M |
| October 08, 2026 | -1.691M |
| October 07, 2026 | -1.385M |
| October 06, 2026 | -1.444M |
| October 05, 2026 | -1.483M |
| October 02, 2026 | -1.552M |
| Date | Value |
|---|---|
| October 01, 2026 | -1.379M |
| September 30, 2026 | -1.030M |
| September 29, 2026 | -1.030M |
| September 28, 2026 | -1.263M |
| September 25, 2026 | -1.263M |
| September 24, 2026 | -1.146M |
| September 23, 2026 | -1.146M |
| September 22, 2026 | -1.379M |
| September 21, 2026 | -1.263M |
| September 18, 2026 | -1.030M |
| September 17, 2026 | -1.146M |
| September 16, 2026 | -1.389M |
| September 15, 2026 | -1.146M |
| September 14, 2026 | -1.030M |
| September 11, 2026 | -1.030M |
| September 10, 2026 | -1.263M |
| September 09, 2026 | -1.030M |
| September 08, 2026 | -1.030M |
| September 04, 2026 | -0.4494M |
| September 03, 2026 | -0.1009M |
| September 02, 2026 | 0.1314M |
| September 01, 2026 | -0.2171M |
| August 31, 2026 | -0.3333M |
| August 28, 2026 | 0.1314M |
| August 27, 2026 | 0.0153M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| CapForce, Inc. | 76.45M |
| Agenus, Inc. | 539.10M |
| Amgen, Inc. | 289.78B |
| Anika Therapeutics, Inc. | 245.53M |
| BioCryst Pharmaceuticals, Inc. | 2.407B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -4.138M |
| Total Expenses (Quarterly) | 4.138M |
| EPS Diluted (Quarterly) | -0.3562 |
| Earnings Yield | -166.1% |
| Normalized Earnings Yield | -166.13 |